MRx-518 is under clinical development by 4D Pharma and currently in Phase II for Transitional Cell Carcinoma (Urothelial Cell Carcinoma). According to GlobalData, Phase II drugs for Transitional Cell Carcinoma (Urothelial Cell Carcinoma) have a 19% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how MRx-518’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
MRx-518 is under development for the treatment of solid tumors like uterine cancer, bladder cancer, non-small cell lung cancer, pancreatic ductal adenocarcinoma (PDAC), liver cancer, urothelial/bladder cancer, renal cell carcinoma, renal cell cancer, melanoma, prostate cancer, ovarian cancer, head and neck cancer and breast cancer. The therapeutic candidate is administered through the oral route. The therapeutic drug candidate constitutes single strain of live biotherapeutic Enterococcus gallinarum. It is developed based on MicroRx technology. The drug candidate acts by targeting the TLR5 receptor. It was also under development for triple negative breast cancer, lung cancer and kidney cancer
4D Pharma overview
4D Pharma formerly 4D Pharma Ltd, is a drug development company. The company discovers and develops bio therapeutics and therapies for the treatment of cancer, gastro-intestinal, autoimmune and CNS diseases. Its pipeline product candidates include MRx0518, a neoadjuvant monotherapy for solid tumors and pancreatic cancer; Blautix, for the treatment of irritable bowel syndrome; MRx-4DP0004 against allergic asthma and coronavirus; and MRx0029 to treat neurodegeneration. It is also evaluating therapies in the areas of oncology, gastro-intestinal, respiratory, and other therapeutic areas. 4D Pharma also offers clinical development services. The company has operational presence in Ireland and Spain. 4D Pharma is headquartered in Leeds, Yorkshire, the UK.
For a complete picture of MRx-518’s drug-specific PTSR and LoA scores, buy the report here.